POU4F1 · Western blot design guide

POU4F1 Western Blot Planning Guide

Plan a POU4F1 Western blot around the catalog-observed 42.7 kDa band, image-backed A05403-1 evidence, HPA controls, and verified protocol records.

Evidence assembled July 2026 · For research use; verify linked source records and product datasheet before use
Western blot protocol sheet for POU4F1 (POU4F1): expected band 42.7 kDa, antibody A05403-1, and guide-derived SDS-PAGE protocol steps
POU4F1 Western blot protocol sheet — expected band 42.7 kDa, antibody A05403-1, controls and PMC citations. Open the full POU4F1 WB guide →

POU4F1 Western Blot Experimental Design Guide

Expected bands, documented protocol parameters, controls and antibodies — the at-a-glance facts below, then the full design guide.

Must know before running
Expected band 42.7 kDa
Observed band Not reported — verify product WB image
Gel 12-15%
Positive control ⓘ Testis
Negative control ⓘ Adipose tissue
Important caveats
Reasons your observed band may differ from the expected size.
ⓘ Calculated mass 42.7 kDa
ⓘ Localization Nucleus / Cytoplasm
ⓘ Processing / PTM Record-dependent
ⓘ Reactivity Human
Section 1

Real Curated POU4F1 Western Blot Protocols

Start with the molecular-weight rule, then compare verified publication-derived conditions.

Recommended Western blot protocol parameters
Sample / lysateRetina
Gel %12-15%
Load20-30 µg total protein per lane
TransferSemi-dry, standard transfer
Membrane0.45 µm PVDF
Blocking5% non-fat milk or 5% BSA in TBST
PrimaryA05403-1 at datasheet starting dilution
Primary incubationOvernight at 4 °C with gentle agitation
SecondarySpecies-matched HRP conjugate at validated dilution
Wash3 × 5 min in TBST
DetectionChemiluminescent substrate
ExposureBracket exposures to avoid saturation
Section 2

What Is the Expected POU4F1 Western Blot Band Size?

Use the product-observed 42.7 kDa band as the primary planning value and retain the UniProt calculated mass as context.

What am I looking at on my blot?
42.7 kDaMatches the authoritative product WB observation.
42.7 kDa calculatedUse as UniProt context, not as a replacement observed band.
Unexpected additional signalDo not assign identity without orthogonal positive/negative controls.
💡Expected POU4F1 appearancePlan around 42.7 kDa and keep the calculated mass as supporting context.
How each factor affects band size
Catalog-observed band42.7 kDa; use this as the primary experimental expectation.
Calculated mass42.7 kDa from UniProt Q01851; retain as context.
Gel selection12-15%; shared with the recommended protocol and poster.
Specificity checkCompare the lead HPA positive and negative controls with A05403-1.
Why is my band missing or off?
SituationLikely causeNext action
42.7 kDaMatches the authoritative product WB observation.Confirm with orthogonal controls and the linked product record.
Additional bandMay reflect processing, modification, or non-specific signal.Run a dilution series and compare positive/negative controls.
Weak signalTarget abundance or transfer may be limiting.Verify transfer, increase positive-control abundance, and bracket exposure.

Sample controls for POU4F1 Western blot

🧪Use Testis as the first positive-control candidate and Adipose tissue as the HPA Not detected negative candidate.
Positive control: Testis (High)
Negative control: Adipose tissue (Not detected)
HPA protein score determines control status; other expression data is supporting context only.

HPA tissue expression evidence for POU4F1

Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.

Positive expression · recommended positive controls

TissueCell typeLevelEvidenceSource
Testis Reported tissue cells High Protein (HPA) HPA →
Retina Reported tissue cells High Protein (HPA) HPA →

Undetected expression · recommended negative controls

TissueCell typeLevelEvidenceSource
Adipose tissue Reported tissue cells Not detected Protein (HPA) HPA →
Adrenal gland Reported tissue cells Not detected Protein (HPA) HPA →
Section 3

Advanced POU4F1 Western Blot Tips

Deeper troubleshooting and optimisation questions for POU4F1, answered from its protein features.

Which band should guide the blot?
Use 42.7 kDa, the observation attached to the authoritative A05403-1 WB record.
How should calculated mass be interpreted?
Treat the UniProt calculated mass as context; it does not replace the catalog-observed 42.7 kDa expectation.
Which positive control should I start with?
Start with Testis, the lead HPA protein-expression candidate.
Which negative control is defensible?
Use Adipose tissue as an orthogonal HPA Not detected candidate.
Which gel should I use?
Use 12-15% consistently across the quick facts, protocol table, and poster.
What transfer method to use for POU4F1 Western blot?
Use the transfer method in the recommended protocol and verify transfer before blocking.
How should A05403-1 be started?
Start at the linked datasheet condition and run a three-point primary-antibody dilution test.
Which publication-derived protocols can I compare?
No verified publication protocol was supplied; use only the deterministic recommended protocol.
Boster reagents

POU4F1 Western Blot Reagents

Human-reactive POU4F1 Western blot reagents with authoritative product imagery.

Real WB data Western blot validation image for POU4F1 using A05403-1; observed band 42.7 kDa
Anti-BRN3A/POU4F1 Antibody Picoband®
Cat # A05403-1

Only image-backed, WB-validated Human/Mouse/Rat recommendations from the prepared catalog evidence are shown.

Source: prepared picoband-wb product evidence; each card retains its own SKU, URL, observed band, and authoritative WB image.

References

  1. UniProt Q01851
  2. Human Protein Atlas — POU4F1
  3. A05403-1 product record
  4. PMC11929989 — Deubiquitinase USP18 mediates cell migration, apoptosis and ferroptosis in lung adenocarcinoma by depending on POU4F1/PRKAA2 axis (BMC cancer, 2025)
  5. PMC7293281 — POU4F1 promotes the resistance of melanoma to BRAF inhibitors through MEK/ERK pathway activation and MITF up-regulation (Cell death & disease, 2020)